Novo Nordisk continues to fully fund Neose’s development work for Factor VIII. The company is also working with Novo Nordisk under separate license agreements to develop long-acting, GlycoPEGylated versions of recombinant Factors VIIa and IX.
George Vergis, president and CEO of Neose, said: “Our collaboration with Novo Nordisk on recombinant Factors VIIa, VIII and IX continues to show great promise, and we are excited about the benefits our GlycoPEGylation technology may provide to Novo in broadening their hemostasis product portfolio.”